{
    "organizations": [],
    "uuid": "e13795f962a7d78ee0074a0a0b3e71e17bfc64ab",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/20/business-wire-acceleron-to-webcast-fourth-quarter-and-full-year-2017-operating-and-financial-results-on-february-27-2018.html",
    "ord_in_thread": 0,
    "title": "Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and full year 2017 operating and financial results.\nThe webcast will be accessible under \"Events & Presentations\" in the Investors/Media page of the company's website at www.acceleronpharma.com . Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the “Acceleron Fourth Quarter and Full Year 2017 Earnings Call.”\nThe archived webcast will be available for replay on the Acceleron website approximately two hours after the event.\nAbout Acceleron\nAcceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.\nAcceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.\nFor more information, please visit www.acceleronpharma.com/ . Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn .\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180220005506/en/\nAcceleron Pharma Inc.\nTodd James, IRC, 617-649-9393\nVice President, Investor Relations and Corporate Communications\nor\nCandice Ellis, 617-649-9226\nManager, Investor Relations and Corporate Communications\nor\nMedia:\nBMC Communications\nBrad Miles, 646-513-3125\nSource: Acceleron Pharma",
    "published": "2018-02-20T15:00:00.000+02:00",
    "crawled": "2018-02-20T18:04:52.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "business",
        "wire",
        "acceleron",
        "pharma",
        "nasdaq",
        "xlrn",
        "today",
        "announced",
        "host",
        "webcast",
        "conference",
        "call",
        "tuesday",
        "february",
        "est",
        "discus",
        "fourth",
        "quarter",
        "full",
        "year",
        "operating",
        "financial",
        "result",
        "webcast",
        "accessible",
        "event",
        "presentation",
        "page",
        "company",
        "website",
        "individual",
        "participate",
        "conference",
        "call",
        "dialing",
        "domestic",
        "international",
        "refer",
        "acceleron",
        "fourth",
        "quarter",
        "full",
        "year",
        "earnings",
        "archived",
        "webcast",
        "available",
        "replay",
        "acceleron",
        "website",
        "approximately",
        "two",
        "hour",
        "event",
        "acceleron",
        "acceleron",
        "biopharmaceutical",
        "company",
        "dedicated",
        "discovery",
        "development",
        "commercialization",
        "therapeutic",
        "treat",
        "serious",
        "rare",
        "disease",
        "company",
        "leadership",
        "understanding",
        "biology",
        "protein",
        "engineering",
        "generates",
        "innovative",
        "compound",
        "engage",
        "body",
        "ability",
        "regulate",
        "cellular",
        "growth",
        "repair",
        "acceleron",
        "focus",
        "research",
        "development",
        "effort",
        "hematologic",
        "neuromuscular",
        "pulmonary",
        "disease",
        "hematology",
        "company",
        "global",
        "collaboration",
        "partner",
        "celgene",
        "developing",
        "luspatercept",
        "treatment",
        "chronic",
        "anemia",
        "myelodysplastic",
        "syndrome",
        "myelofibrosis",
        "acceleron",
        "also",
        "advancing",
        "neuromuscular",
        "franchise",
        "two",
        "distinct",
        "agent",
        "pulmonary",
        "program",
        "phase",
        "trial",
        "sotatercept",
        "planned",
        "pulmonary",
        "arterial",
        "hypertension",
        "information",
        "please",
        "visit",
        "follow",
        "acceleron",
        "social",
        "medium",
        "acceleronpharma",
        "linkedin",
        "view",
        "source",
        "version",
        "http",
        "acceleron",
        "pharma",
        "todd",
        "james",
        "irc",
        "vice",
        "president",
        "investor",
        "relation",
        "corporate",
        "communication",
        "candice",
        "elli",
        "manager",
        "investor",
        "relation",
        "corporate",
        "communication",
        "medium",
        "bmc",
        "communication",
        "brad",
        "mile",
        "source",
        "acceleron",
        "pharma"
    ]
}